A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis

NCT03432260 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Alcoholic Hepatitis

Interventions

DRUG: DUR-928 30 mg
DRUG: DUR-928 90 mg
DRUG: DUR-928 150 mg

Sponsor

Durect

Collaborators

[object Object]